Kewaunee Scientific (KEQU) Q4 2026 earnings summary

Executive summary

• FY2026 revenue reached $282.0M, reflecting a 17.3% increase and global leadership in laboratory infrastructure and solutions.

• Integrated Kewaunee Scientific, NuAire, and EVERHUTCH into the Lab Products Group, enhancing efficiency, customer value, and expanding the domestic platform.

• Five-year revenue increased 91% and EBITDA grew over 112x, demonstrating transformational value creation.

• EBITDA rose to $22.425M, reflecting operational resilience and strategic investments.

• Significant balance sheet improvements included debt reduction and completion of Seller Note repayment.

Financial highlights

• FY2026 net sales reached $281.999M, up from $240.472M in FY2025 and $203.755M in FY2024.

• FY2026 operating profit was $16.715M (5.9% of sales), with adjusted operating profit at $17.5M (6.2%).

• FY2026 net earnings were $9.618M, or $10.223M adjusted for NuAire integration costs.

• Q4 FY2026 net sales were $71.4M, with adjusted net earnings of $3.404M and adjusted diluted EPS of $1.14.

• EBITDA for FY2026 was $22.425M, or $23.210M adjusted.

Outlook and guidance

• Strategic focus on operational excellence, customer proximity, and innovation to drive future growth.

• Management expects continued execution of growth strategy in FY27, focusing on disciplined capital allocation and operational excellence.

• Positioned for sustained growth and long-term value creation through integrated platform and expanded capabilities.

• The company is positioned for improved performance as life sciences market conditions recover.